Suchergebnisse - "Shi, Yuankai"

PubPharm (8)

1

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

enthalten in: Chinese journal of cancer | 2019

von Zhou, M. | Chen, X. | Zhang, H. | +14

2

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

enthalten in: Chinese journal of cancer | 2019

von Shi, Y. | Li, J. | Xu, J. | +19

3

Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial

enthalten in: Chinese journal of cancer | 2018

von Qin, Y. | Song, Y. | Shen, Z. | +5

4

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma

enthalten in: Chinese journal of cancer | 2015

von Shi, Y. | Zhou, P. | Han, X. | +11

5

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

enthalten in: Chinese journal of cancer | 2015

von Shi, Y. | Zhou, P. | Han, X. | +11

6

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

enthalten in: Chinese journal of cancer | 2015

von Shi, Y. | Zhou, P. | Han, X. | +11

7

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma

enthalten in: Chinese journal of cancer | 2015

von Shi, Y. | Zhou, P. | Han, X. | +11

8

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin?s lymphoma

enthalten in: Chinese journal of cancer | 2015

von Shi, Y. | Zhou, P. | Han, X. | +11

1
[1]